RPCG PCL F (R4Q) - Net Assets
Based on the latest financial reports, RPCG PCL F (R4Q) has net assets worth €3.83 Billion EUR (≈ $4.48 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€9.20 Billion ≈ $10.76 Billion USD) and total liabilities (€5.37 Billion ≈ $6.27 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RPCG PCL F liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.83 Billion |
| % of Total Assets | 41.66% |
| Annual Growth Rate | 14.54% |
| 5-Year Change | 121.42% |
| 10-Year Change | N/A |
| Growth Volatility | 23.13 |
RPCG PCL F - Net Assets Trend (2016–2024)
This chart illustrates how RPCG PCL F's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of RPCG PCL F for the complete picture of this company's asset base.
Annual Net Assets for RPCG PCL F (2016–2024)
The table below shows the annual net assets of RPCG PCL F from 2016 to 2024. For live valuation and market cap data, see R4Q market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.87 Billion ≈ $4.53 Billion |
-3.13% |
| 2023-12-31 | €4.00 Billion ≈ $4.67 Billion |
+62.88% |
| 2022-12-31 | €2.45 Billion ≈ $2.87 Billion |
-0.63% |
| 2021-12-31 | €2.47 Billion ≈ $2.89 Billion |
+41.22% |
| 2020-12-31 | €1.75 Billion ≈ $2.04 Billion |
+0.94% |
| 2019-12-31 | €1.73 Billion ≈ $2.03 Billion |
+28.60% |
| 2018-12-31 | €1.35 Billion ≈ $1.57 Billion |
+2.78% |
| 2017-12-31 | €1.31 Billion ≈ $1.53 Billion |
+0.28% |
| 2016-12-31 | €1.31 Billion ≈ $1.53 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to RPCG PCL F's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 126335285100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €799.08 Million | 33.97% |
| Other Components | €1.55 Billion | 66.03% |
| Total Equity | €2.35 Billion | 100.00% |
RPCG PCL F Competitors by Market Cap
The table below lists competitors of RPCG PCL F ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Seelos Therapeutics, Inc.
NASDAQ:SEELQ
|
$58.00 |
|
WM Technology Inc
NASDAQ:MAPSW
|
$65.35 |
|
Jack Nathan Medical Corp
V:JNH
|
$67.14 |
|
Seneca Growth Capital VCT PLC
LSE:HYG
|
$69.12 |
|
Godha Cabcon & Insulation Limited
NSE:GODHA
|
$56.06 |
|
Future Enterprises Limited
NSE:FEL
|
$49.18 |
|
Prairie Lithium Limited
AU:PL9
|
$48.63 |
|
Zivo Bioscience Inc. Warrants
NASDAQ:ZIVOW
|
$45.75 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RPCG PCL F's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,479,087,458 to 2,352,168,578, a change of -126,918,880 (-5.1%).
- Net loss of 71,922,430 reduced equity.
- Dividend payments of 52,185,913 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-71.92 Million | -3.06% |
| Dividends Paid | €52.19 Million | -2.22% |
| Other Changes | €-2.81 Million | -0.12% |
| Total Change | €- | -5.12% |
Book Value vs Market Value Analysis
This analysis compares RPCG PCL F's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.99 | €0.01 | x |
| 2018-12-31 | €1.02 | €0.01 | x |
| 2019-12-31 | €1.32 | €0.01 | x |
| 2020-12-31 | €1.34 | €0.01 | x |
| 2021-12-31 | €1.89 | €0.01 | x |
| 2022-12-31 | €1.88 | €0.01 | x |
| 2023-12-31 | €1.90 | €0.01 | x |
| 2024-12-31 | €1.80 | €0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RPCG PCL F utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.81%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 4.05x
- Recent ROE (-3.06%) is below the historical average (4.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -5.36% | -3.07% | 0.71x | 2.45x | €-198.51 Million |
| 2017 | -2.83% | -1.50% | 0.78x | 2.41x | €-166.36 Million |
| 2018 | -0.67% | -0.27% | 0.92x | 2.65x | €-142.26 Million |
| 2019 | 22.15% | 8.89% | 1.05x | 2.36x | €208.91 Million |
| 2020 | 2.54% | 1.06% | 0.90x | 2.66x | €-130.52 Million |
| 2021 | 28.19% | 12.70% | 1.38x | 1.61x | €449.03 Million |
| 2022 | 2.61% | 0.82% | 1.89x | 1.68x | €-181.37 Million |
| 2023 | 1.12% | 0.27% | 1.14x | 3.64x | €-220.11 Million |
| 2024 | -3.06% | -0.81% | 0.93x | 4.05x | €-307.14 Million |
Industry Comparison
This section compares RPCG PCL F's net assets metrics with peer companies in the Specialty Retail industry.
Industry Context
- Industry: Specialty Retail
- Average net assets among peers: $680,410,950
- Average return on equity (ROE) among peers: 22.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RPCG PCL F (R4Q) | €3.83 Billion | -5.36% | 1.40x | $56.92 |
| JUMBO SA UNSP.ADR/1 O.N. (5JB1) | $1.33 Billion | 16.31% | 0.35x | $3.23 Billion |
| SEALAND CAP. GA. LS-0001 (7KM) | $-1.58 Million | 0.00% | 0.00x | $765.46K |
| SFD SA ZY -10 (7PQ) | $47.27 Million | 26.53% | 1.19x | $28.55 Million |
| BETTERWARE DE MEXICO SAPI (BM0) | $1.20 Billion | 145.95% | 3.32x | $566.11 Million |
| Brüder Mannesmann Aktiengesellschaft (BMM) | $9.70 Million | -9.46% | 2.93x | $4.05 Million |
| Ceconomy AG (CEC) | $4.02 Billion | 5.82% | 4.57x | $2.02 Billion |
| DUFRY AG UNSP.ADR/010 (D2JA) | $966.10 Million | 6.02% | 8.64x | $7.78 Billion |
| Dunelm Group plc (DFQ) | $281.20 Million | 45.84% | 1.73x | $2.00 Billion |
| Douglas AG (DOU) | $-1.29 Billion | 0.00% | 0.00x | $1.12 Billion |
| Mister Spex SE (MRX) | $244.78 Million | -12.87% | 0.33x | $44.94 Million |
About RPCG PCL F
RPCG Public Company Limited, together with its subsidiaries, engages in the energy and real estate businesses in Thailand. It operates through Energy, Real Estate Development, Rental, Service, and Restaurant and Bakery segments. The company is involved in the manufacture and distribution of biodiesel and crude glycerin; Pico plus business; systems management; general service; retail of fuel and g… Read more